Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
Status:
Unknown status
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
The treatment of the patients with metastatic breast cancer remains a major problem. However,
there is an intermediate state between the primary tumor and distant metastases called
oligometastasis. Current research indicates that good local control of oligometastasis can be
obtained with Stereotactic body radiotherapy (SBRT) Can not prolong the long-term survival of
patients. Researchers believe that after SBRT treatment of patients with oligometacosis in
breast cancer, it is necessary to explore whether the anti-angiogenic therapy targeted drug
apatinib can reduce the occurrence of new lesions and prolong the survival of patients.